Expertise in
9
conditions

Jean-pierre P. Quenot

Dijon, FR 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
9
conditions
Dijon, FR 

Overview

Jean-pierre Quenot practices practicing medicine in Dijon, France.

Quenot is highly rated in 9 conditions, according to our data. Their clinical expertise encompasses Sepsis, Pneumonia, Acute Respiratory Distress Syndrome (ARDS), and Severe Acute Respiratory Syndrome (SARS).

They are actively involved in clinical research, co-authoring 279 peer reviewed articles and participating in 16 clinical trials.

Locations

Dijon, France
Other Locations
Bourgogne, France
Paris, France
Le Havre, France
Rennes, France
Poitiers, France
France
Nantes, France
Lyon, 86000, France
Limoges, France
Angers, France
Clermont-ferrand, France
Montpellier, France
3, Boulevard Fleming, Besancon, 25030, France
Nancy, France
Brive-la-gaillarde, France
INSERM CIC 1402, And CIC 1435, Point A-Pitre All In France, Montauban, France
Nimes, France
AP HP & Université Paris Est, 51, Av De Lattre De Tassigny, Creteil, 94000, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

16 Clinical Trials

Effect of Early Use of Levosimendan Versus Placebo on Top of a Conventional Strategy of Inotrope Use on a Combined Morbidity-mortality Endpoint in Patients With Cardiogenic Shock
Effect of Early Use of Levosimendan Versus Placebo on Top of a Conventional Strategy of Inotrope Use on a Combined Morbidity-mortality Endpoint in Patients With Cardiogenic Shock
Enrollment Status: Recruiting
Publish Date: August 05, 2025
Intervention Type: Drug
Study Drug: Levosimendan
Study Phase: Phase 3
Multi-centre, Adaptive, Randomized Trial of the Safety and Efficacy of Treatments of COVID-19 in Hospitalized Adults
Multi-centre, Adaptive, Randomized Trial of the Safety and Efficacy of Treatments of COVID-19 in Hospitalized Adults
Enrollment Status: Completed
Publish Date: July 08, 2026
Intervention Type: Other, Drug
Study Drugs: Remdesivir, Lopinavir, Ritonavir, Interferon Beta-1A, Hydroxychloroquine, AZD7442
Study Phase: Phase 3
Impact on Mortality of the Timing of Renal Replacement Therapy in Patients With Severe Acute Kidney Injury in Septic Shock: the IDEAL-ICU Study (Initiation of Dialysis Early Versus Delayed in the Intensive Care Unit): Study Protocol for a Randomized Controlled Trial
Impact on Mortality of the Timing of Renal Replacement Therapy in Patients With Severe Acute Kidney Injury in Septic Shock: the IDEAL-ICU Study (Initiation of Dialysis Early Versus Delayed in the Intensive Care Unit): Study Protocol for a Randomized Controlled Trial
Enrollment Status: Terminated
Publish Date: February 09, 2026
Intervention Type: Procedure
Study Phase: Phase 3
Impact of Socio-economic Vulnerability on Initial Severity and Prognosis in Patients Admitted to an ICU. Prospective, Multi-centre Cohort Study
Impact of Socio-economic Vulnerability on Initial Severity and Prognosis in Patients Admitted to an ICU. Prospective, Multi-centre Cohort Study
Enrollment Status: Completed
Publish Date: February 09, 2026
Intervention Type: Other
Study Phase: Not Applicable
Effects of Low-dose Corticosteroids on Survival of Severe Community-acquired Pneumonia
Effects of Low-dose Corticosteroids on Survival of Severe Community-acquired Pneumonia
Enrollment Status: Completed
Publish Date: December 22, 2025
Intervention Type: Drug
Study Drug: Hydrocortisone
Study Phase: Phase 3
Early Versus Differed Arterial Catheterization in Critically Ill Patients With Acute Circulatory Failure: A Multicentre, Open-label, Pragmatic, Randomised, Non-inferiority Controlled Trial (EVERDAC Trial)
Early Versus Differed Arterial Catheterization in Critically Ill Patients With Acute Circulatory Failure: A Multicentre, Open-label, Pragmatic, Randomised, Non-inferiority Controlled Trial (EVERDAC Trial)
Enrollment Status: Completed
Publish Date: December 22, 2025
Intervention Type: Procedure
Study Phase: Not Applicable
Double-blinded Multicenter Randomized Controlled Trial Comparing Inhaled Amikacin Versus Placebo to Prevent Ventilator Associated Pneumonia
Double-blinded Multicenter Randomized Controlled Trial Comparing Inhaled Amikacin Versus Placebo to Prevent Ventilator Associated Pneumonia
Enrollment Status: Completed
Publish Date: December 22, 2025
Intervention Type: Drug
Study Drug: Amikacin
Study Phase: Phase 3
Evaluation of Prone Position in Conscious Patients on Nasal High-flow Oxygen Therapy for COVID-19 Disease Induced Acute Respiratory Distress Syndrome
Evaluation of Prone Position in Conscious Patients on Nasal High-flow Oxygen Therapy for COVID-19 Disease Induced Acute Respiratory Distress Syndrome
Enrollment Status: Completed
Publish Date: December 22, 2025
Intervention Type: Other
Study Phase: Not Applicable
Adjunctive DobutAmine in sePtic Cardiomyopathy With Tissue Hypoperfusion: a Randomized Controlled Multi-center Trial
Adjunctive DobutAmine in sePtic Cardiomyopathy With Tissue Hypoperfusion: a Randomized Controlled Multi-center Trial
Enrollment Status: Completed
Publish Date: November 21, 2025
Intervention Type: Drug
Study Drug: Dobutamine
Study Phase: Phase 3
L-carnitine as an Adjunct Treatment for Septic Shock Patients With Acute Kidney Injury: a Multicentre, Randomized, 2-parallel Group, Superiority Trial
L-carnitine as an Adjunct Treatment for Septic Shock Patients With Acute Kidney Injury: a Multicentre, Randomized, 2-parallel Group, Superiority Trial
Enrollment Status: Terminated
Publish Date: August 26, 2025
Intervention Type: Drug
Study Drug: L-Carnitine
Study Phase: Phase 3
View 9 Less Clinical Trials

279 Total Publications

HydrOcortisone and fludRocortisoNe for critical ILLness-related corticosteroid insufficiency (HORNbILL): study protocol for a multicentre randomised placebo-controlled trial.
HydrOcortisone and fludRocortisoNe for critical ILLness-related corticosteroid insufficiency (HORNbILL): study protocol for a multicentre randomised placebo-controlled trial.
Journal: BMJ open
Published: June 17, 2026

Frequently Asked Questions about Jean-pierre P. Quenot

Is Jean-pierre P. Quenot a top-rated expert for Sepsis?

MediFind is an objective health platform that identifies experts based on real-world data. Jean-pierre P. Quenot is classified as an Distinguished expert for Sepsis, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Jean-pierre P. Quenot participate in research or clinical trials?

Yes. Jean-pierre P. Quenot has published 279 articles and abstracts on conditions like Sepsis. You can view a list of Jean-pierre P. Quenot's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Quenot's expertise for a condition
ConditionClose
    View All 7 Advanced Conditions
    View All 21 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile